Discovery of CVN417, a Novel Brain-Penetrant a6-Containing Nicotinic Receptor Antagonist for the Modulation of Motor Dysfunction. (2023)
Attributed to:
Defining the striatal dopamine signals that enable movement: a high resolution spatiotemporal characterisation
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1021/acs.jmedchem.3c00630
PubMed Identifier: 37651656
Publication URI: http://europepmc.org/abstract/MED/37651656
Type: Journal Article/Review
Volume: 66
Parent Publication: Journal of medicinal chemistry
Issue: 17
ISSN: 0022-2623